Skip to main content

Table 11 Neurological conditions

From: Benefits and harms of medical cannabis: a scoping review of systematic reviews

Author, year {refid}

Search dates; # databases searched

Funding source

Nstudies

Illness/condition

Intervention/comparator

Outcomes

Conclusions from data

AMSTAR-2 rating

Baldinger, 2012 [50]

To Jan 2011 and Cochrane specialized register to Feb 14, 2011; 4

Non-profit

1

ALS/motor neuron disease

I: Plant-derived cannabinoids

C: Placebo

• Muscle cramps

• Muscle cramps as AEs

No statistically significant difference between groups

L

Gloss, 2014 [72]

Searched on Sept 9, 2013; 6

NR

4

Epilepsy

I: Plant-derived cannabinoids

C: placebo

• Seizure freedom for 12 months

No studies assessed primary outcome in this review

M

Krishnan, 2009 [59]

Dec 2005–Apr 2008; 6

NR

1

Dementia

I: Synthetic cannabinoids

C: Placebo

• Body weight

• Triceps skinfold thickness

• Disturbed behavior

• Affect

Only one study included

L

Hanson, 2011 [74]

Jan 1990 to Oct 2009; 5

Government

1

Dementia

I: Synthetic cannabinoids

C: placebo

• Weight

• Negative affect

• Disruptive behavior

Only one study included

L

CADTH, 2018 [83]

Jan 1 2012 to Nov 29, 2017; 6

No funding

4

Dementia

I: Plant-derived cannabinoids

C: Placebo

• Static balance

• Dynamic balance

• Stride length

• Total AEs

• Dizziness

• Somnolence

• Balance disorders

• Falls

• Severe AEs

Only one study included

CL

  1. AE adverse effect, ALS amyotrophic lateral sclerosis, CADTH Canadian Agency for Drugs and Technologies in Health, NR not reported